Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study).

Michael Bauer,Andreas Weyland,Gernot Marx,Frank Bloos, Stephan Weber,Norbert Weiler,Stefan Kluge, Anja Diers,Tim Philipp Simon,Ingmar Lautenschläger,Matthias Gründling,Ulrich Jaschinski,Philipp Simon,Axel Nierhaus,Onnen Moerer, Lorenz Reill,Achim Jörres,Renfeng Guo,Markus Loeffler,Konrad Reinhart,Niels Riedemann

Critical care explorations（2021）

引用 15|浏览6

暂无评分

摘要

Administration of vilobelimab in patients with severe sepsis and septic shock selectively neutralizes C5a in a dose-dependent manner without blocking formation of the membrane attack complex and without resulting in detected safety issues. The data warrant further investigation of C5a inhibition in sepsis.

查看译文

关键词

adult,antibodies,complement C5a,humans,monoclonal,sepsis/*drug therapy/immunology,treatment outcome

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要